Takeshi Shono

First‐Line Lorlatinib in Striatin–Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma: A Case Report and Literature Review

Striatin–anaplastic lymphoma kinase (STRN–ALK) is a rare fusion variant in non‐small cell lung cancer (NSCLC), and the efficacy of first‐line lorlatinib for this subgroup is poorly defined. We report a 45‐year‐old treatment‐naïve male with STRN‐ALK‐positive lung adenocarcinoma and symptomatic brain metastases. Followin...